Navamedic — M&A Activity 2014

May 5, 2014

Navamedic expands cooperation with Aspen

Navamedic expands cooperation with Aspen

Navamedic ASA (OSE: NAVA) today announced an expansion of the Company's

cooperation with generic pharmaceuticals manufacturer Aspen of South Africa.

Navamedic assumes responsibility for products representing additional NOK 40

million in annual sales.

Aspen, the largest pharmaceuticals company in the southern hemisphere, has been

Navamedic's main supplier since 2010. Navamedic markets and distributes Aspen

products in the Nordic and Benelux markets.

Aspen acquired a portfolio of pharmaceuticals for the European market from MSD

last year. Starting immediately, Navamedic will market and distribute the

majority of these products in the Nordic markets on Aspen's behalf. The products

now being included in Navamedic's portfolio represent annual sales of

approximately NOK 40 million in these markets. Navamedic had total revenues of

NOK 152 million last year.

Navamedic has also renegotiated its previous agreements with Aspen, improving

the Company's overall profitability from its relationship with the South African

pharmaceuticals group.

"The renewed and expanded cooperation with Aspen establishes an even stronger

platform for Navamedic. We will continue to pursue growth in the Nordic markets

and further improve the Company's profitability," said Navamedic's acting CEO

Håkan Josephsson.

For further information, please call Håkan Josephsson, interim CEO, telephone

+46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and

distributing more than 100 products in the Nordic and Benelux markets. The

Company operates three business areas; Pharma Products, Medical Nutrition and

Consumer Care based on its relationship with a number of pharmaceutical product

manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

[HUG#1782576]